Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations

被引：10

作者：

Porta, Camillo ^{[1
,2
]}

Bamias, Aristotelis ^{[3
]}

Zakopoulou, Roubini ^{[3
]}

Myint, Zin W. ^{[4
]}

Cavasin, Nicola ^{[5
]}

Iacovelli, Roberto ^{[6
]}

Pichler, Martin ^{[7
]}

Kopecky, Jindrich ^{[8
]}

Kucharz, Jakub ^{[9
]}

Rizzo, Mimma ^{[1
]}

Galli, Luca ^{[10
]}

Buettner, Thomas ^{[11
]}

De Giorgi, Ugo ^{[12
]}

Kanesvaran, Ravindran ^{[13
]}

Fiala, Ondrej ^{[14
,15
]}

Grande, Enrique ^{[16
]}

Zucali, Paolo A. ^{[17
,18
]}

Kopp, Ray M. ^{[19
]}

Fornarini, Giuseppe ^{[20
]}

Bourlon, Maria T. ^{[21
]}

Scagliarini, Sarah ^{[22
]}

Molina-cerrillo, Javier ^{[23
]}

Aurilio, Gaetano ^{[24
]}

Matrana, Marc R. ^{[25
]}

Pichler, Renate ^{[26
]}

Cattrini, Carlo ^{[27
]}

Buechler, Tomas ^{[28
,29
,30
,31
]}

Massari, Francesco ^{[32
,69
]}

Mollica, Veronica ^{[32
]}

Seront, Emmanuel ^{[33
]}

Calabro, Fabio ^{[34
]}

Pinto, Alvaro ^{[35
]}

Berardi, Rossana ^{[36
]}

Zgura, Anca ^{[37
]}

Mammone, Giulia ^{[38
]}

Ansari, Jawaher ^{[39
]}

Atzori, Francesco ^{[40
]}

Chiari, Rita ^{[41
]}

Caffo, Orazio ^{[42
]}

Procopio, Giuseppe ^{[43
,44
]}

Sunela, Kaisa ^{[45
]}

Bassanelli, Maria ^{[46
]}

Ortega, Cinzia ^{[47
]}

Grillone, Francesco ^{[48
]}

Landmesser, Johannes ^{[49
]}

Merler, Sara ^{[50
]}

Messina, Carlo ^{[51
]}

Kueronya, Zsofia ^{[52
]}

Mosca, Alessandra ^{[53
]}

Bhuva, Dipen ^{[54
]}

机构：

[1] AOU Consorziale Policlin Bari, Div Med Oncol, Bari, Italy

[2] Aldo Moro Univ Bari, Chair Oncol, Interdisciplinary Dept Med, Bari, Italy

[3] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Med Sch, Dept Internal Med 2, Athens, Greece

[4] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA

[5] Ist Oncol Veneto IOV IRCCS, Dept Oncol, Oncol Unit 3, Padua, Italy

[6] IRCCS A Gemelli Univ Polyclin Fdn, Oncol Med, Rome, Italy

[7] Med Univ Graz, Dept Internal Med, Div Oncol, Graz, Austria

[8] Univ Hosp Hradec Kralove, Dept Clin Oncol & Radiotherapy, Hradec Kralove, Czech Republic

[9] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Urooncol, Warsaw, Poland

[10] Univ Hosp Pisa, Oncol Unit 2, Pisa, Italy

[11] Univ Hosp Bonn UKB, Dept Urol, Bonn, Germany

[12] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Dept Med Oncol, Forli Cesena, Italy

[13] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore

[14] Charles Univ Prague, Fac Med, Dept Oncol & Radiotherapeut, Plzen, Czech Republic

[15] Charles Univ Prague, Univ Hosp Pilsen, Plzen, Czech Republic

[16] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain

[17] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[18] IRCCS Humanitas Res Hosp, Dept Oncol, Milan, Italy

[19] Soc Oncol & Hematol Cesar, Clin Oncol, Valledupar, Colombia

[20] IRCCS San Martino Univ Hosp, Genoa, Italy

[21] Salvador Zubiran Natl Inst Med & Nutr Sci, Dept Hematol & Oncol, Mexico City, Mexico

[22] Azienda Osped Rilievo Nazl Cardarelli Naples, Unit Oncol, Naples, Italy

[23] Hosp Raman y Cajal, Dept Med Oncol, Madrid, Spain

[24] European Inst Oncol IEO IRCCS, Med Oncol Div Urogenital Head Neck Tumors, Milan, Italy

[25] Ochsner Med Ctr, Dept Internal Med Hematol Oncol, New Orleans, LA USA

[26] Med Univ Innsbruck, Dept Urol, Innsbruck, Austria

[27] Maggiore della Carita Univ Hosp, Dept Med Oncol, Novara, Italy

[28] Charles Univ Prague, Fac Med 1, Dept Oncol, Prague, Czech Republic

[29] Thomayer Univ Hosp, Prague, Czech Republic

[30] Charles Univ Prague, Fac Med 2, Dept Oncol, Prague, Czech Republic

[31] Motol Univ Hosp, Prague, Czech Republic

[32] IRCCS Azienda Osped Univ Bologna, Med Oncol, Bologna, Italy

[33] Jolimont Hosp Ctr, Dept Med Oncol, Haine St Paul, Belgium

[34] San Camillo Forlanini Hosp, Dept Radiat Oncol, Rome, Italy

[35] La Paz Univ Hosp, Dept Med Oncol, Madrid, Spain

[36] Univ Politecn Marche, AOU Osped Riuniti, Dept Med Oncol, Ancona, Italy

[37] Carol Davila Univ Med & Pharm, Prof Dr Alexandru Trestioreanu Inst Oncol, Dept Oncol Radiotherapy, Bucharest, Romania

[38] Sapienza Univ Rome, Dept Radiol Oncol & Anatomo Pathol Sci, Rome, Italy

[39] Tawam Hosp, Dept Med Oncol, Al Ain, U Arab Emirates

[40] Univ Hosp Cagliari, Unit Med Oncol, Cagliari, Italy

[41] Azienda Osped Osped Riuniti Marche Nord, Unit Oncol, Pesaro, Italy

[42] Santa Chiara Hosp, Unit Med Oncol, Trento, Italy

[43] IRCCS Ist Nazl Tumori Fdn, Dept Med Oncol, Milan, Italy

[44] Osped Maggiore Cremona, Dept Med Oncol, Cremona, Italy

[45] Tampere Univ Hosp, Tays Canc Ctr, Dept Oncol, Tampere, Finland

[46] IRCCS Regina Elena Natl Canc Inst, Dept Med Oncol 1, Rome, Italy

[47] Asl Cn2 Alba Bra, Inst Canc Res & Treatment, Div Oncol, Alba, Cuneo, Italy

[48] Pugliese Ciaccio Hosp, Unit Med Oncol, Catanzaro, Italy

[49] Clin Urol, Lubeck, Germany

[50] Univ Verona, Verona Univ Hosp, Dept Med, Sect Oncol,Sch Med, Verona, Italy

来源：

MINERVA UROLOGY AND NEPHROLOGY | 2023年 / 75卷 / 04期

关键词：

Immunotherapy; Nephrectomy; Carcinoma; renal cell; Survival; THERAPY;

D O I：

10.23736/S2724-6051.23.05369-7

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND: The upfront treatment of metastatic renal cell carcinoma (mRCC) has been revolutionized by the in-troduction of immune-based combinations. The role of cytoreductive nephrectomy (CN) in these patients is still debated. The ARON-1 study (NCT05287464) was designed to globally analyze real-world data of mRCC patients receiving first -line immuno-oncology combinations. This sub-analysis is focused on the role of upfront or delayed partial or radical CN in three geographical areas (Western Europe, Eastern Europe, America/Asia).METHODS: We conducted a multicenter retrospective observational study in mRCC patients treated with first-line im-mune combinations from 55 centers in 19 countries. From 1152 patients in the ARON-1 dataset, we selected 651 patients with de novo mRCC. 255 patients (39%) had undergone CN, partial in 14% and radical in 86% of cases; 396 patients (61%) received first-line immune-combinations without previous nephrectomy.RESULTS: Median overall survival (OS) from the diagnosis of de novo mRCC was 41.6 months and not reached (NR) in the CN subgroup and 24.0 months in the no CN subgroup, respectively (P<0.001). Median OS from the start of first -line therapy was NR in patients who underwent CN and 22.4 months in the no CN subgroup (P<0.001). Patients who underwent CN reported longer OS compared to no CN in all the three geographical areas.CONCLUSIONS: No significant differences in terms of patients' outcome seem to clearly emerge, even if the rate CN and the choice of the type of first-line immune-based combination varies across the different Cancer Centers participating in the ARON-1 project.

引用

页码：460 / 470

页数：11

共 17 条

[1] Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium [J].

Bakouny, Ziad ;

El Zarif, Talal ;

Dudani, Shaan ;

Wells, J. Connor ;

Gan, Chun Loo ;

Donskov, Frede ;

Shapiro, Julia ;

Davis, Ian D. ;

Parnis, Francis ;

Ravi, Praful ;

Steinharter, John A. ;

Agarwal, Neeraj ;

Alva, Ajjai ;

Wood, Lori ;

Kapoor, Anil ;

Morales, Jose M. Ruiz ;

Kollmannsberger, Christian ;

Beuselinck, Benoit ;

Xie, Wanling ;

Heng, Daniel Y. C. ;

Choueiri, Toni K. .

EUROPEAN UROLOGY, 2023, 83 (02) :145-151

[2]

CARMENA Trial, 2019, Eur Urol Oncol, V2, P340

[3] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Powles, T. ;

Burotto, M. ;

Escudier, B. ;

Bourlon, M. T. ;

Zurawski, B. ;

Juarez, V. M. Oyervides ;

Hsieh, J. J. ;

Basso, U. ;

Shah, A. Y. ;

Suarez, C. ;

Hamzaj, A. ;

Goh, J. C. ;

Barrios, C. ;

Richardet, M. ;

Porta, C. ;

Kowalyszyn, R. ;

Feregrino, J. P. ;

Zolnierek, J. ;

Pook, D. ;

Kessler, E. R. ;

Tomita, Y. ;

Mizuno, R. ;

Bedke, J. ;

Zhang, J. ;

Maurer, M. A. ;

Simsek, B. ;

Ejzykowicz, F. ;

Schwab, G. M. ;

Apolo, A. B. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841

[4] Systemic Therapy for Metastatic Renal-Cell Carcinoma [J].

Choueiri, Toni K. ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (04) :354-366

[5] Renal cell carcinoma [J].

Hsieh, James J. ;

Purdue, Mark P. ;

Signoretti, Sabina ;

Swanton, Charles ;

Albiges, Laurence ;

Schmidinger, Manuela ;

Heng, Daniel Y. ;

Larkin, James ;

Ficarra, Vincenzo .

NATURE REVIEWS DISEASE PRIMERS, 2017, 3

[6] European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update [J].

Ljungberg, Borje ;

Albiges, Laurence ;

Abu-Ghanem, Yasmin ;

Bedke, Jens ;

Capitanio, Umberto ;

Dabestani, Saeed ;

Fernandez-Pello, Sergio ;

Giles, Rachel H. ;

Hofmann, Fabian ;

Hora, Milan ;

Klatte, Tobias ;

Kuusk, Teele ;

Lam, Thomas B. ;

Marconi, Lorenzo ;

Powles, Thomas ;

Tahbaz, Rana ;

Volpe, Alessandro ;

Bex, Axel .

EUROPEAN UROLOGY, 2022, 82 (04) :399-410

[7] Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials [J].

Massari, Francesco ;

Rizzo, Alessandro ;

Mollica, Veronica ;

Rosellini, Matteo ;

Marchetti, Andrea ;

Ardizzoni, Andrea ;

Santoni, Matteo .

EUROPEAN JOURNAL OF CANCER, 2021, 154 :120-127

[8] Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy [J].

Massari, Francesco ;

Di Nunno, Vincenzo ;

Gatto, Lidia ;

Santoni, Matteo ;

Schiavina, Riccardo ;

Cosmai, Laura ;

Brunocilla, Eugenio ;

Ardizzoni, Andrea ;

Porta, Camillo .

TARGETED ONCOLOGY, 2018, 13 (06) :705-714

[9] Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma [J].

Mejean, A. ;

Ravaud, A. ;

Thezenas, S. ;

Colas, S. ;

Beauval, J. -B. ;

Bensalah, K. ;

Geoffrois, L. ;

Thiery-Vuillemin, A. ;

Cormier, L. ;

Lang, H. ;

Guy, L. ;

Gravis, G. ;

Rolland, F. ;

Linassier, C. ;

Lechevallier, E. ;

Beisland, C. ;

Aitchison, M. ;

Oudard, S. ;

Patard, J. -J. ;

Theodore, C. ;

Chevreau, C. ;

Laguerre, B. ;

Hubert, J. ;

Gross-Goupil, M. ;

Bernhard, J. -C. ;

Albiges, L. ;

Timsit, M. -O. ;

Lebret, T. ;

Escudier, B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (05) :417-427

[10] Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma [J].

Motzer, R. J. ;

Tannir, N. M. ;

McDermott, D. F. ;

Frontera, O. Aren ;

Melichar, B. ;

Choueiri, T. K. ;

Plimack, Elizabeth R. ;

Barthelemy, P. ;

Porta, C. ;

George, S. ;

Powles, T. ;

Donskov, F. ;

Neiman, V. ;

Kollmannsberger, C. K. ;

Salman, P. ;

Gurney, H. ;

Hawkins, R. ;

Ravaud, A. ;

Grimm, M. -O. ;

Bracarda, S. ;

Barrios, C. H. ;

Tomita, Y. ;

Castellano, D. ;

Rini, B. I. ;

Chen, A. C. ;

Mekan, S. ;

McHenry, M. B. ;

Wind-Rotolo, M. ;

Doan, J. ;

Sharma, P. ;

Hammers, H. J. ;

Escudier, B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (14) :1277-1290

← 1 2 →